Investor
Rosalind Advisors, Inc.
CIK 0001622627 · filed 2026-05-14 · SEC filing
13F book
$248.9M
Positions
32
11 new · 8 sold
Largest name
12.3%
Delcath Sys Inc
Est. mark
−$31.1M
Price effect on 21 names still held. Flow $720K.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Delcath Sys Inc | — | 3.3M | $30.6M | 12.3% | −$2.38M | Held |
| Xeris Biopharma Holdings, Inc. | XERS | 3.23M | $18.7M | 7.5% | −$4.33M | Added$2.17M |
| Fennec Pharmaceuticals Inc. | FENC | 2.91M | $17.9M | 7.2% | −$4.05M | Added−$2.24M |
| Savara Inc | SVRA | 3.2M | $17.5M | 7.0% | −$1.83M | Cut−$3.03M |
| Vaxcyte, Inc. | PCVX | 290K | $16.9M | 6.8% | — | New |
| EyePoint, Inc. | EYPT | 1.04M | $13.4M | 5.4% | −$3.71M | Added$757.2K |
| X4 Pharmaceuticals, Inc | XFOR | 3.21M | $13.3M | 5.3% | $338.8K | Added$2.85M |
| Vor Biopharma Inc. | VOR | 700K | $12.5M | 5.0% | — | New |
| MediWound Ltd. | MDWD | 749.1K | $12.1M | 4.8% | −$1.76M | Held |
| Verastem, Inc. | VSTM | 2.14M | $11.3M | 4.6% | −$4.33M | Added−$2.47M |
| Celldex Therapeutics Inc New | — | 330K | $10.5M | 4.2% | — | New |
| Biocryst Pharmaceuticals Inc | BCRX | 923.1K | $8.79M | 3.5% | — | New |
| Cybin Inc. | HELP | 1.53M | $7.35M | 3.0% | −$5.18M | Cut−$6.21M |
| CG Oncology, Inc. | CGON | 100K | $6.77M | 2.7% | $2.62M | Cut−$5.69M |
| InspireMD, Inc. | NSPR | 3.91M | $6.37M | 2.6% | −$585.9K | Held |
| Atea Pharmaceuticals, Inc. | AVIR | 1.17M | $6.3M | 2.5% | — | New |
| Profound Med Corp | — | 828.1K | $5.37M | 2.2% | −$1.15M | Cut−$3.05M |
| Viridian Therapeutics Inc | — | 250.4K | $4.9M | 2.0% | −$2.89M | Cut−$9.11M |
| PolyPid Ltd. | PYPD | 597.9K | $2.62M | 1.1% | $23.9K | Cut−$404.1K |
| Myomo, Inc. | MYO | 3.85M | $2.6M | 1.0% | −$900K | Added−$895K |
| Talphera, Inc. | TLPH | 3.35M | $2.51M | 1.0% | −$1.32M | Cut−$1.58M |
| Ovid Therapeutics Inc. | OVID | 1.11M | $2.46M | 1.0% | — | New |
| Definium Therape | DFTX | 125K | $2.36M | 0.9% | — | New |
| OnKure Therapeutics, Inc. | OKUR | 443.8K | $1.84M | 0.7% | $550.3K | Cut−$281.2K |
| Lipocine Inc New | — | 221.6K | $1.77M | 0.7% | — | New |
| Neuraxis, INC | NRXS | 286.1K | $1.69M | 0.7% | $654.7K | Held |
| Avalo Therapeutics, Inc. | AVTX | 75K | $1.12M | 0.4% | — | New |
| Annexon, Inc. | ANNX | 200K | $1.11M | 0.4% | — | New |
| Aquestive Therapeutics, Inc. | AQST | 250K | $1.04M | 0.4% | — | New |
| Biofrontera Inc | — | 1.16M | $941.6K | 0.4% | $272.6K | Added$291.4K |
| Kura Oncology, Inc. | KURA | 100K | $813K | 0.3% | −$226K | Held |
| Regentis Biomaterials Ltd. | RGNT | 251.5K | $768.4K | 0.3% | −$926.8K | Held |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.